Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...